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Objective:
 
 The objective of this study was to examine
the cost-effectiveness of preventive treatment with in-
terferon beta (IFNB) versus no preventive treatment in
patients with multiple sclerosis.
 
Methods:
 
 The setting for this study was the United King-
dom. A lifetime Markov process model was constructed
to model the average quality-adjusted life years (QALYs)
and the costs of both treatment strategies. Data for the
construction of the model came from published literature,
including large multicenter randomized clinical trials in
relapsing-remitting and secondary progressive multiple
sclerosis. Costs were obtained from published sources.
 
Results:
 
 The results of the baseline analysis from the
National Health Service (NHS) perspective showed that
the use of interferon beta as preventive treatment for
MS increased the total average discounted cost from
£51,214 to £221,436 per patient. The undiscounted ef-
 
fectiveness increased from 24.9 QALYs to 28.2 QALYs,
resulting in an incremental cost-effectiveness ratio of
£51,582 per QALY. Sensitivity analyses showed the ro-
bustness of this model for other interferons.
 
Conclusion:
 
 The study showed that preventive treat-
ment with interferon beta in patients with multiple scle-
rosis may not be fully justified from a health-economic
perspective, although interferon beta is associated with
an improved effectiveness compared with no preventive
treatment.
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Introduction
 
Epidemiology
 
Multiple sclerosis (MS) is the second most common
cause of neurological disability in young and mid-
dle-aged adults [1,2]. Females are more susceptible
by a factor that approaches 2:1 in population stud-
ies, but this varies among surveys [1]. Males are
more likely to have progressive disease from onset
[3,4]. The mean age of onset of MS is during the
third and fourth decades of life with a peak inci-
dence during the late 20s to early 30s [5,6].
Most patients initially have the relapsing-remit-
ting form (RRMS) with a variable frequency of
exacerbations (mean 1–2 per year). At onset, 65%
of patients fall into the RRMS category [3,6]. Even-
tually most RRMS patients will develop the sec-
ondary progressive form (SP). In this stage, fewer
exacerbations occur, and recovery from them is al-
ways incomplete. Eventually no recovery is possi-
ble. In addition, a chronic and slow increase in
neurological deficits takes place. Thus, the patient
suffers from increasingly severe disability [7–10].
 
Quality of Life
 
It is generally recognized that MS can dramatically
affect the quality of life (QoL) experienced by an
afflicted patient and/or his/her family. Many MS
patients have a normal life span and have to live
with some degree of disability over a prolonged
time period. Family life, economic status, and social
interaction may be affected by somatic symptoms
of the disease [11]. Cognitive dysfunction affects
43% to 65% of MS patients and also has a major
negative influence on QoL in MS patients. Cogni-
tively impaired patients are less likely to be profes-
sionally active, are more dependent, report more
sexual dysfunction and tend to be less socially en-
gaged than cognitively intact MS patients [12].
 
Economic Impact of Multiple Sclerosis
 
The full economic cost of MS to society and to the
individuals concerned is uncertain, but is most
likely to be substantial, bearing in mind that:
1. MS patients experience a major perturbation in
their daily activities.
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2. MS affects mainly young, productive people
between the ages of 25 and 40 [1] who are
obliged to interrupt their professional activities
either temporarily or permanently [13].
A positive correlation between total health-care
costs and the Expanded Disability Status Scale
(EDSS) has been demonstrated among MS pa-
tients. At EDSS scores of 5.5 (needs aid to walk)
and higher, costs increased particularly quickly
[13].
Few economic studies of MS have been pub-
lished. A prevalence-based cost-of-illness study in
the United Kingdom (1995) estimated the annual
burden of MS at £1199 million [14]. The largest
share was carried by the state, and the total cost
included the following: state benefits, £287 mil-
lion (23.9%); National Healthcare System (NHS)
costs (hospitalization, other treatment, and sup-
port), £153 million (12.8%); and lost tax revenue
£148 million (12.3%). Annual NHS costs range
from £336 to at least £4275 per patient depending
on their level of mobility, which influences the
number of hospital in-patients visits. The costs for
drugs were insignificant (£23/patient [
 

 
 2%] in-
terferon not included). Lost earnings (33%), pri-
vate expenses (11.7%) and employer’s expenses
(6.3%) were higher. The authors suspected that
this total cost value was an underestimation in that
diagnostic costs were not completely assessed and
the use of average (general population) values for
consultation time may not have been accurate for
MS patients. In an earlier study conducted in En-
gland and Wales, the annual costs of the disease
were estimated at £125.4 million (1986–1987
prices). In this study, the largest component (20%)
was the lost earnings of MS sufferer, although the
cost burden on the family was not considered
[15]. A more recent cross-sectional cost-of-care
study was performed to assess the economic bur-
den of multiple sclerosis (MS) in the United King-
dom, France, and Germany [16]. Patients were
stratified into three severity groups according to
the EDSS: stages I, II, and III, corresponding to
mild (EDSS 1.0–3.5), moderate (EDSS 4.0–6.0)
and severe (EDSS 6.5–8.0) MS, respectively. From
the societal perspective, the total cost of MS for 3
months was estimated at £3500, £4612 and £9989
per patient for stages I, II, and III patients, respec-
tively, in the United Kingdom. From the health-
insurance perspective, the cost for 3 months was
estimated at £535, £616 and £2020 in the United
Kingdom per patient with stage I, II, and III MS,
respectively.
Indirect costs tend to be the largest contributors
to the overall cost burden. Taking into account
employment history, medical insurance, amount
and source of family income and disease progres-
sion, MS can cost an individual 40% of their life-
time earnings [13,17,18]. Recent studies have in-
dicated that 50% to 80% of MS patients are
unemployed within 10 years of disease onset [19–
21]. As mentioned for the UK study, indirect costs
related to lost earnings represented £395 million
per annum or 33.0% of the total burden. Of this,
26.3% was attributed to lost earnings of nonpro-
fessional caregivers. It has also been reported that
39% of men and 19% of women with MS retire
early because of disability, with one of the most
frequently cited reasons being MS-related fatigue
[22]. Cognitive impairment, spasticity, perturba-
tion of coordination and disturbances of bladder
and bowel functions, nonremittent disease course,
heavy physical work, and age over 30 years may
be factors contributing to early retirement or un-
employment [20,23,24].
A previous cost-effectiveness study was per-
formed for preventive treatment with interferon
beta in patients with initial RRMS [25]. This
study was based on a modeling design following
patients over a period of 5 and 10 years. The
study showed that the additional cost of inter-
feron beta (INFB) of £43,400 is offset by gains in
QALYs of 0.13, indicating a cost-utility ratio of
£328,300 per QALY gained. The 10-year analysis
produced a slightly more favorable cost-effective-
ness ratio of £228,300. This study could not take
into account the potential reduction in disease
progression associated with use of interferon beta
in patients who had already progressed to SP be-
cause clinical data documenting the favorable ef-
fect of interferons in SP were not yet available.
 
Treatment of Multiple Sclerosis
 
We will focus on the prevention of disease activity
by interferons. The rationale for such therapy is
that MS is generally thought of as an autoimmune
disease. Interferons have, by definition, antiviral
properties, but they also have immunomodulating
and antiproliferative properties. The classification
of interferons as IFN
 

 
, IFN
 

 
, and IFN
 

 
 is based
on their antigenicity and the similarities of their
nucleotide sequences. Two types of recombinant
IFN
 

 
 exist, IFN
 

 
-1a and IFN
 

 
-1b. IFN
 

 
 and
IFN
 

 
 are used in the treatment of MS because of
their immunomodulatory capacity to suppress the
activated immune system. A major effect is thought
to occur through the blocking of IFN
 

 
 effects,
 46
 
Nuijten and Hutton
 
which activate the immune system [26–29]. A ma-
jor breakthrough in the treatment of RRMS pa-
tients is evident in the recent results of clinical tri-
als in which recombinant IFN beta (IFN
 

 
-1b or
IFN
 

 
-1a) was shown to significantly reduce the
relapse rate [20,30,31]. IFN
 

 
-1b was the first of
the interferons tested in a large-scale clinical trial
in RRMS and SP.
The IFN
 

 
-1b results in RRMS were based on
pooled results from 3-year, multicenter, random-
ized, double-blind, placebo-controlled clinical trials
each with three parallel treatment groups (placebo
vs. 1.6 MIU vs. 8 MIU IFN
 

 
-1b) [30]. All patients
in the study were given the option of continuing
treatment in a double-blind fashion, extending the
total treatment period to 5.5 years for a portion of
patients. Subsequently, two studies with IFNa-1a
were performed in RRMS patients [20,32].
1. The results of all interferon beta trials are com-
parable [30,32]. All the IFNs reduce the re-
lapses in MS.
2. The IFN
 

 
s have a positive effect on delaying
progression in disability over the two- to 3-year
trial period.
3. These effects of IFN
 

 
s are dose related. Debate
over dosage exists, and although the approved
dosage should be given; the highest tolerable
dose is preferred.
The IFN
 

 
-1b results in SP were based on a 3-year,
multicenter, randomized, double-blind, placebo-
controlled clinical trial with patients receiving ei-
ther 8 MIU interferon or placebo [31]. This was the
first clinical study that showed that interferons
might delay disease progression in patients with SP.
In the event that the favorable effect of interfer-
ons on the frequency of acute exacerbations and
disease activity may have an impact on cost-effec-
tiveness, the present study uses a modeling tech-
nique to compare the cost-effectiveness of inter-
feron beta with no preventive treatment in patients
with MS in the United Kingdom. The hypothesis is
that interferons will lead to a long-term reduction
in disease activity, including acute exacerbations
and disease progression (change in disability over
time defined as change in EDSS), and a decrease in
morbidity leading to an increased quality of life,
which will offset the expected increased drug costs.
 
Methods
 
To estimate the costs and effectiveness of preven-
tive treatment with interferon beta in patients with
MS versus usual care in the health-care setting of
the United Kingdom, a lifetime model was con-
structed using decision-analysis techniques [33,34].
The main analytical plan for the study was an in-
cremental cost-effectiveness analysis. This approach
consists of combining cumulative measures of costs
over time with a cumulative measure of effective-
ness, resulting in incremental costs per clinical
benefit gained (e.g., cost per life-year gained). The
analysis was performed for a hypothetical cohort
of 30-year-old female patients with initial RRMS,
i.e., patients whose clinical picture was character-
ized by periods of exacerbation (relapse) from
which recovery was complete or partial with sub-
sequent mild disability. For a more specific mea-
sure of impairment, the Expanded Disability Sta-
tus Scale (EDSS) was used [35]. In general, the
inclusion criteria used in the clinical trials of inter-
feron beta were used. Effectiveness was expressed
as quality-adjusted life years (QALYs). The model
also included all relevant economic measures such
as resource utilization patterns associated with
outpatient and inpatient care for the treatment of
MS, indirect costs (working days lost) and direct,
nonmedical costs.
The setting of the study was the UK health-care
system of 1998. The primary perspective of the
study was that of the NHS according to the NICE
guidelines [36], while the secondary perspective
was that of the society in 1998. Costs used in the
model were expressed in 1998 sterling pounds (£),
and study costs were adjusted to 1998 costs from
1996 costs by using a 4.3% inflation correction
[37]. The cost valuation was based on the direct
health-care costs, direct nonmedical costs and indi-
rect costs. The costs were discounted by 6% from
the second year onwards, and no discounting was
applied in the first year. The data sources were lit-
erature, including clinical trials of interferon beta
and other interferons, and official price and tariff
lists. An external opinion leader validated the meth-
odology (model structure and assumptions).
 
Description of the Model
 
Markov-process analysis techniques were used to
model the clinical and economic outcomes accrued
over a lifetime with or without preventive treat-
ment. An advantage of the Markov process model
is that it allows modeling of MS disease progression
beyond the follow-up of the clinical trials.
Figure 1 shows the structure of the Markov
model for MS. The model structure for the usual-
care treatment arm is identical. The first branch
point on a tree is called a decision node because it
 Cost-Effectiveness of Interferon in MS
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Figure I Simplified version of the semi-Markov model for the base case scenario. Only the sub-tree after interferon beta is
shown for feasibility purposes.
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corresponds to a choice of treatment — interferon
beta or usual care. A decision node is represented
as a small square (
 

 
). Subsequent to the decision
node, the structure of the semi-Markov process
model is shown, and is identical for both treat-
ment options. The other branch points indicate al-
lowed transitions per cycle. The cycle time chosen
for the model was 3 years, which closely approxi-
mates the follow-up period for the interferon beta
clinical trials in RRMS and in secondary progres-
sive MS. The follow-up time (analytical horizon)
used in the model was the remainder of the life-
time after diagnosis of RRMS.
For this analysis we defined mutually exclusive
Markov states. Initially we defined Markov health
states corresponding with severity levels of MS:
1. Stage I: EDSS 
 

 
 3.5
2. Stage II: EDSS 4–6.5
3. Stage III: EDSS 7–9.5
4. DEAD: EDSS 
 

 
 10
Because the primary outcome variable in most
clinical trials was defined as deterioration from
baseline by at least 1.0 point on the EDSS for at
least 3 months, the health states indicated above
have been further categorized to allow for the in-
corporation of clinical trial results in the model:
stage I-2.5 corresponds with an average EDSS of
2.5; stage I-3.5 with an average EDSS 
 

 
 3.5, etc.
Finally DEAD corresponds with an EDSS of 10.
In the model, all patients start in the health
state “stage I-2.5”, which corresponds to the aver-
age EDSS of patients in the interferon beta clinical
trial at inclusion. After one cycle of 3 years there
are two possibilities: a patient will stay in “stage
I-2.5” if the EDSS score has not changed by more
than 1; a patient will move to “stage I-3.5” after a
worsening of the EDSS score of more than 1.
In addition, there will be a number of patients
on preventive treatment who drop out during the
first cycle period because of adverse events, which
means that they will receive no treatment for the
remainder of the follow-up period in the model.
stage I-2.5 has been divided in stage I-2.5-1 and
stage I-2.5-2 to reflect noncompliance during the
first cycle (stage I-2.5-1) and full compliance dur-
ing subsequent cycles (stage I-2.5-2).
Therefore the health states were further catego-
rized into Treatment (T) or No Treatment (NT).
 
Key Model Assumptions
 
There are a number of key assumptions upon
which the model is based. A 3-year cycle time was
used, because this interval closely approximates
the follow-up period of the interferon beta clinical
trials for preventive treatment in RRMS and sec-
ondary progressive MS.
 
Follow-Up
 
A study by Runmarker et al. [38] showed that
only 20% of the patients progressed to SP after 25
years. Therefore, we decided to construct a life-
time model, which allowed us to simulate the re-
duction in disease progression by interferon beta
in real life more realistically.
In the model, all patients start in the health
state stage I-2.5 with an average EDSS of 2.5,
which corresponds with the average EDSS of the
patients in the beta interferon clinical trial in RRMS
(IFN
 

 
-1b 2.4, placebo 2.3). Hence, the model is
based on a hypothetical patient with an EDSS
score of 2.5.
The model was based on an analysis of high-
dose interferon beta, because prospective clinical
studies have been performed in RRMS as well as
in SP.
Follow-up for estimating the effect of preven-
tive treatment with interferon beta in RRMS and
secondary progressive MS are available for up to 3
years. Follow-up data for the no-preventive-treat-
ment arm came from follow-up data for the pla-
cebo arms of interferon clinical trials. Disease pro-
gression is based on the definitions that are used
in the clinical trials: worse 
 

 
 change in EDSS 
 

 
1;
stable 
 

 
 no change in EDSS.
 
Disease Progression
 
1. Stage I, EDSS 
 

 
4.5. Disease progression was
based on the IFN
 

 
-1b clinical trial in RRMS
(mean EDSS at inclusion 
 

 
 2.4);
2. Stage II, EDSS 4.5–7.5. Disease progression
was based on the IFN
 

 
-1b clinical trial in sec-
ondary progressive MS (mean EDDS at inclu-
sion 
 

 
 5.2);
3. Stage III, EDSS 7.5–9.5. We assumed that be-
yond the actual follow-up period for the trial
of IFN
 

 
-1b in secondary progressive MS, all
treatment strategies have the same rate of dis-
ease progression and use the disease progres-
sion for placebo from clinical trials as a state
transition matrix in the Markov process. Hence,
although the disease progression can differ dur-
ing the actual follow-up period of the clinical
trials as a result of the treatment, progression
beyond this period is assumed to be the same
whether patients received preventive treatment
 Cost-Effectiveness of Interferon in MS
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or not, although this may be an underestima-
tion of the effectiveness of IFN
 

 
-1b.
4. EDSS 9.5 until death. We assumed that there
was no difference in mortality between patients
with or without preventive treatment.
Noncompliance was derived from the IFN
 

 
-1b
trial in RRMS only. We assumed that noncompli-
ance occurred only during the first cycle of our
model and was due only to adverse events. Conse-
quently, noncompliance data from the interferon
beta clinical trial in SP was not used because pa-
tients in the IFN
 

 
-1b clinical trial in SP started
treatment with IFN
 

 
-1b, which does not corre-
spond with patients in our model who had already
proved to be compliant.
 
Acute Exacerbations
 
1. Stage I 
 

 
 EDSS 
 

 
4.5. The incidence of acute
exacerbations was based on the IFN
 

 
-1b clini-
cal trial in RRMS.
2. Stage II 
 

 
 EDSS 4.5–7.5. The incidence of
acute exacerbations was based on the IFN
 

 
-1b
clinical trial in SP.
3. Stage III 
 

 
 EDSS 7.5–9.5. We assumed that SP
patients in stage III did not experience exacerba-
tions anymore, and consequently assumed no
benefit in terms of preventing acute exacerba-
tions with IFN
 

 
-1b beyond the actual follow-up
period of the interferon beta clinical trials.
The initial cohort in the model consisted of 30-
year-old women, based on literature data. The
mean age of onset for MS is during the late 20s
and early 30s, and females are more susceptible by
a factor of 2:1 [1].
Age-specific mortality rates for women were
used, assuming that MS did not alter life expect-
ancy. Literature did not yield evidence for an in-
creased mortality risk due to MS.
 
Clinical and Economic Outcomes
 
Effectiveness.
 
The effectiveness measurement was
based on the concept of utility, which measures
the QALY [39,40].
 
Cost Assessment.
 
The cost assessment was based
on the assignment of costs to the health states as-
sociated with a cycle time of 3 years. The costs of
each health state were determined by the resource
utilization associated with each health state: medi-
cal resource utilization (e.g., medication, consulta-
tions) and nonmedical resource utilization. Non-
medical resource utilization included workdays
 
lost, transportation, community assistance, and
home modifications.
 
Data Sources
 
Three different types of data can be distinguished
in modeling studies:
1. Probabilities of clinical events, which generally
are out of the control of the physician, e.g.,
probability of an acute exacerbation, disease
progression;
2. Utilities of different Markov health states; and
3. Costing information derived from estimates of
the units of resource utilization and their
prices/tariffs (product of unit and price).
The probabilities of clinical events were based
on interferon beta clinical trial data, while the util-
ities and costs were derived from two cross-sec-
tional studies. The prices and tariffs were derived
from official lists.
 
Probabilities
 
Probabilities were derived from published litera-
ture (Table 1):
1. Stage I: EDSS 
 

 
 2.5–4.5: probabilities of dis-
ease progression and incidence of acute exacer-
bations derived from the interferon beta clini-
cal trial in RRMS.
2. Stage II: EDSS 
 

 
 4.5–7.5: probabilities of dis-
ease progression and incidence of acute exacer-
bations derived from the interferon beta clini-
cal trial in secondary progressive MS.
3. Stage III: EDSS 8.5 to death: probabilities of
disease progression derived from a meta-analy-
sis of the placebo-treated groups in clinical tri-
als in progressive MS [18].
4. Age-specific population mortality rates for women
derived from national statistics data [22].
 
Utilities
 
The QALYs for the different health states were de-
rived from a cross-sectional study and are shown
in Table 2 [29]. The classification of disease sever-
ity in this study corresponds with semi-Markov
health states in our model. We also incorporated a
temporary utility loss per relapse, which was de-
rived from the same study—a reduction of 0.5
utility over a period of 1 month.
 
Costs
 
Data on costs were derived from another cross-
sectional study (Table 3) [16]. This study used a
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retrospective approach in which resource utiliza-
tion and clinical data were collected at a single
point in time and covered the 3-month period
prior to the dates of inclusion.
The cost of care of MS was calculated for pa-
tients in current clinical practice in the United
Kingdom in 1996, which did not include costs of
preventive treatments like interferons. Therefore
the cost of interferon beta was added to health
states corresponding to preventive treatment (“T-
health states”).
The costs due to relapses were not separately
presented in the cost-of-care study. Therefore we
subtracted the costs of avoided exacerbations from
the costs of health states that included preventive
treatment with interferon beta. The direct medical
costs due to an exacerbation were derived from the
cost-effectiveness study in initial RRMS [25].
The friction cost method was applied to the
evaluation of workdays lost by active patients. Ac-
cording to this method, the value of productivity
loss was assumed to be 80% of the average value
of a worker’s productivity during the “friction pe-
riod.” Thereafter, it was assumed that sick em-
ployees could be replaced. Time lost by inactive
patients was considered as leisure time lost and was
valued at 40% of the average wage in the United
Kingdom [41]. The replacement salary method (i.e.,
estimation of the wage that would be paid to a
home helper to perform the work that the patient
was unfit to do) was applied to the valuation of
care-giving time [42]. We assumed that the num-
ber of working days lost associated with a relapse
corresponded with relapse length, which was de-
rived from the same study.
 
Analyses
 
The base-case analysis represents the expected aver-
age effectiveness and costs per patient discounted at
6%; undiscounted costs were also included. An in-
cremental cost-effectiveness analysis representing
the additional cost and effectiveness obtained when
 
Table 2
 
Utilities for health states. Health Technology 
Assessment, 1998 [25]
 
Health state Utility
EDDS utilities Stage Fixed input value
EDDS-3 I 0.71
EDDS-4 II 0.66
EDDS-5 II 0.52
EDDS-6 II 0.49
EDDS-7 III 0.35
EDDS-8* III 0.17
EDDS-9* III 0.08
DEAD 0.00
Utility loss
Relapse 0.5
 
*Extrapolation.
EDDS, Expanded Disability Status Scale.
[25] Parkin D, McNamee P, Jacoby A, et al. A cost utility analysis of interferon
beta for multiple sclerosis. 1998;2:iii54–64.
 
Table 3
 
Costs for health states, excluding cost of 
interferon, 1998 [16]
 
Health state Costs (£)
Perspective mean median Reference
Societal Murphy 1998
- Stage I 3,500 2,829
- Stage II 4,612 3,266
- Stage III 9,989 6,906
Health insurance
- Stage I 535 361
- Stage II 616 348
- Stage III 2,020 682
Health Technology
Assessment 1998
Cost per relapse 2,115
Annual costs INFB 10,500
INFB
 
INFB, interferon beta.
[16] Murphy N, Confavreux C, Haas J, Economic Evaluation of Multiple Sclero-
sis in the UK, Germany and France. Pharmacoeconomics 1998;13:607–22.
 
Table 1
 
Clinical data and sources
 
RRMS
Probability
per cycle Reference
From EDSS 
 

 
 2.5 to EDSS
 

 
 4.5
Continuation after first cycle
INFB 8 MIU 0.920 [30]
Progression placebo 0.28 Idem
Progression INFB 8 MIU 0.20 Idem
Progression interferons
minimum* 0.193 [20]
maximum* 0.219 Idem
SP
From EDSS 
 

 
 4.5 to EDSS 
 

 
 7.5
Progression placebo 0.50 [31]
Progression interferon INFB
8MIU 0.39 Idem
From EDSS 
 

 
 8.5 to death 0.31 [3]
Exacerbations
Annual
frequency
From EDDS 
 

 
 2.5 to EDSS 
 

 
 4.5
Placebo 1.21 [30]
Interferon 0.84 Idem
Difference 0.37
From EDDS 
 

 
 4.5 to EDSS 
 

 
 7.5 [31]
Placebo 0.64
Interferon 0.44
Difference 0.20
From EDDS 
 

 
 8.5 to Death 0 Assumption
 
*Adjustment of 2- to 3-year probabilities.
RRMS, relapsing-remitting multiple sclerosis; EDSS, Expanded Disability Status
Scale; SP, secondary progressive.
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a preventive treatment with interferon beta is com-
pared with no treatment was also performed.
 
Sensitivity Analysis
 
Univariate sensitivity analyses were based on the
modification of the basic clinical and economic as-
sumptions in the clinical-outcome model to test
the stability of the conclusions of the analysis over
a range of assumptions, probability estimates,
and value judgments. Sensitivity analyses were per-
formed only for the primary perspective of this
study, that of the NHS.
The first sensitivity analysis was performed to
assess the impact of relapses on the analysis by ex-
cluding the clinical and economic consequences of
relapses. We performed a second analysis to assess
the sensitivity of the analysis to the annual costs of
interferon beta. The bounds for this analysis were
based on annual costs of other interferon treat-
ments. A third sensitivity analysis was performed
for the cost of a relapse. The costs per relapse in the
study by Health Technology Assessment included
both ambulatory treatment and hospitalization. Be-
cause this input variable had a wide range of val-
ues, the model was potentially highly sensitive to it
[25]. A fourth sensitivity analysis was performed on
the costs of the health stages derived from the study
by Murphy [16] (Table 2) by using median costs of
all three health stages instead of the mean costs.
The fifth sensitivity analysis involved constructing
an interval around the rate of disease progression.
The bounds for this analysis were based on the
rates of disease progression in RRMS, which have
been published for other interferons. The rates were
adjusted to transition probabilities corresponding
to a 3-year cycle time.
The three previous sensitivity analyses were
performed from the NHS perspective only. We
also performed a sensitivity analysis on a 3% dis-
count rate from the societal perspective according
to the guidelines of 
 
Value in Health
 
.
 
Results
 
Based on the probabilities, utilities, and the costs
of the direct health-care utilization described in
Tables 1, 2, and 3, a base-case analysis was per-
formed to obtain an expected value for the aver-
age total costs and the average QALY. Tables 4
and 5 show the economic and effectiveness out-
comes of the base-case analysis for preventive
treatment with interferon beta and no preventive
treatment in MS from the third-party payer and
societal perspectives, respectively.
The total average discounted cost per patient
for the preventive treatment of an MS patient
starting from RRMS was £221,436 for the inter-
feron beta group versus £51,214 for the no-treat-
ment group (discounted at an annual rate of 6%).
A breakdown of the costs shows that the higher
costs of the interferon group are attributed to the
cost of interferons (£179,367), while the other
costs were £51,214 and £42,069 for the no-treat-
ment group and interferon group, respectively.
Based on the model, the average QALY of the
interferon group was 28.2 years versus 24.9 years
for the no-treatment group (Table 4), a gain in
QALYs of 3.3 years. The differences in cost and
effectiveness resulted in an incremental cost-effec-
tiveness for interferon beta of £51,582 per QALY
gained.
Table 5 shows the results of an analysis from
the societal perspective. The total average discounted
cost per patient for preventive treatment of an MS
 
Table 4
 
Results of cost-effectiveness: Health insurance
 
INFB Usual care Difference
Undiscounted costs (£)
INFB 498,505 0
Other 161,475 210,824
Total 659,980 210,824 449,156
Discounted costs (£)*
INFB 179,367 0
Other 42,069 51,214
Total 221,436 51,214 170,222
Effectiveness
QALYs 28.2 24.9 3.3
Cost per QALY gained:
Discounted costs and QALYs 51,582
 
*Discounting at 6%.
INFB, interferon beta; QALY, quality-adjusted life years.
 
Table 5
 
Results of cost-effectiveness analysis from societal 
perspective
 
INFB Usual care Difference
Undiscounted costs (£)*
INFB 498,505 0
Other 1,032,212 1,209,409
Total 1,530,717 1,209,409 321,308
Discounted costs (£)*
INFB 179,367 0
Other 293,748 322,499
Total 473,115 322,499 150,616
Effectiveness
QALYs 28.2 24.9 3.3
 
*Discounting at 6%.
INFB, interferon beta; QALY, quality-adjusted life years.
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patient was higher in the interferon beta group at
£473,115 versus £322,499 for the no-treatment
group, discounted at 6% per annum. The use of
interferons substantially reduced the other costs
from £322,499 to £293,748.
 
Sensitivity Analysis
 
Sensitivity analyses were performed on the main
probabilities and cost assumptions to test the ro-
bustness of the cost-effectiveness results. Table 5
shows the results of the sensitivity analyses. The
first two sensitivity analyses were performed to as-
sess the impact of discounting. They show that the
incremental cost-effectiveness ratio is quite sensi-
tive to discounting of both economic and clinical
outcomes. A sensitivity analysis was also per-
formed to assess the impact of relapses on the in-
cremental cost-effectiveness ratio. When the cost
of relapse and the utility loss due to relapse were
excluded, the incremental cost-effectiveness of in-
terferon beta was £38,222 compared with the
base case result of £51,582, which shows that the
model is moderately sensitive to the inclusion of
relapses. A sensitivity analysis was also performed
on the annual cost of IFN-1b (Table 6). When
the annual cost is varied from £6,000 to £12,000,
the incremental cost-effectiveness ratio changes sub-
stantially from £28,280 to £59,348. When the med-
ical cost of a relapse is varied between its lower
and higher range (£1000 to £3000), the incremental
cost-effectiveness ratio changes only from £47,028
to £50,275. We also performed a sensitivity analy-
sis on the disease progression with interferon beta.
When this was varied between minimum and max-
imum values, the incremental cost-effectiveness ra-
tio increased from £43,520 to £56,756. Finally a
sensitivity analysis was performed on a 3% dis-
count rate for both costs and effectiveness, which
shows that the use of interferon beta increased the
costs from £510,940 to £701,410, while the QALYs
increased from 24,98 to 28,12.
Discussion
This study examined the cost-effectiveness of pre-
ventive treatment with interferon beta compared
with no preventive treatment of patients with MS
in a British setting. The analysis revealed that in-
terferons were much more cost-effective compared
with the results of a previous cost-effectiveness
study that was performed in patients with RRMS
only [25]. The incremental cost-effectiveness ratio
in our study was £51,582 per QALY, while the
outcomes in the other study were £328,300 and
£228,300 per QALY over a period of 5 and 10
years, respectively. This substantial reduction in
the cost-effectiveness ratio of interferon beta may
be due to a longer follow-up period in our study,
including continuation of treatment with inter-
feron beta in SP. Sensitivity analysis showed that
our model was especially sensitive to discounting,
the cost of interferon beta, and disease progres-
sion. The results of this study showed that cost-
effectiveness of a preventive treatment with inter-
feron beta in MS substantially improves when its
use in SP is incorporated in the health-economic
analysis.
The results of any modeling exercise need to be
treated with some degree of caution. We have
used various data sources for our model, all of
which have their pros and cons [21] from a
health-economic perspective. Among them is the
fact that our literature review does not necessarily
represent real clinical practice, in that much of the
literature examined was based on data from clini-
cal trials. Data from clinical trials do not necessar-
ily have a high degree of external validity because
the results are often contingent upon protocol ad-
Table 6 Results of sensitivity analysis
Variable Range of values Cost per QALY gained
Health insurance perspective Discounted
Basis 51,582
No discounting of costs 136,108
Discounting of effectiveness (2%) 113,108
Excluding relapses 38,222
Annual costs INFB (£) 6,000–12,000 28,280–59,348
Medical relapse cost 1,000–3,000 47,028–50,275
Disease progression RMMS: 0.193–0.219SP: 0.351–0.429 43,520–56,756
Societal perspective Extra costs (£) QALYs gained
Discounting of costs and effectiveness at 3% 199,470 3,14
QALYs, quality-adjusted life years.
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herence, a situation that may not be easily repro-
duced outside the trial setting. The utilities in our
model were derived from a cross-sectional study
based on clinical treatment practice without the
use of preventive treatment with interferon beta.
The utility of a health state is a function of both
underlying disease (e.g., severity) and adverse events
associated with treatment. In our model we valued
the health states only according to severity levels
corresponding to the EDSS severity scale regard-
less of the use of preventive treatment with beta
interferon. Hence, the assumption in our model
was that treatment with interferons did not affect
the utility of the health states. Consequently the
utilities did not take into account a potential lower
utility of health states associated with interferon
treatment due to adverse events. Finally we did
not include the costs associated with treatment of
adverse events resulting from treatment with inter-
feron beta, and so may have underestimated the
total costs for preventive treatment.
Modeling of disease progression was constrained
by published clinical trial data. Those data were
presented as the percentage of patients staying at
the same EDSS level or moving to a worse EDSS
level, which may have involved more than one
transition. However, the published data did not
show more detailed data, which may be a result of
statistical constraints: interferon may indeed re-
duce the number of patients progressing more
than one EDSS level, but the statistical significance
of this effect may be more difficult to prove.
Finally the study focused mainly on the cost-
effectiveness of IFN-1b 8 MIU only, demonstrat-
ing robustness of the outcomes of the model when
using clinical trial data from other interferons. A
meta-analysis based on pooled results of the vari-
ous interferon trials may have lead to more reli-
able input data for the model. However, this ap-
proach was not feasible for a number of reasons:
there was only one trial in SP that showed that in-
terferon beta reduces disease progression; dose re-
lationships did not allow us to cluster the different
interferons and determine average rates; and clini-
cal trials did not have similar follow-up. The
IFN-1b trial had a follow-up period of 3 years,
while other trials had a follow-up of only 2 years;
populations in the trials in RRMS were not simi-
lar, which is shown by different placebo outcomes
as well as initial EDSS scores.
Comparing the modeled disease progression for
no preventive treatment with real-life data from a
study by Runmarker et al. [38] quantitatively vali-
dated our model, which did not include preventive
treatment with interferons. After 24 years, ap-
proximately 18% of the patients in our model
progressed to SP. This outcome corresponds with
findings in the study by Runmarker et al. [38],
where 20% progressed to SP after 25 years. A lim-
itation in the study by Runmarker may be the
small number of patients and the inclusion of pa-
tients with progressive MS, which may explain the
slower disease progression in our model.
Conclusion
In conclusion, the study showed that preventive
treatment with interferon beta in patients with
multiple sclerosis may not be fully justified from a
health-economic perspective, although interferon
beta is associated with an improved effectiveness
compared with no preventive treatment. Develop-
ment of clinical guidelines may be used to optimize
the cost-effectiveness outcomes and budgetary con-
straints. A suitable approach is the prospective col-
lection of health economic data and utilities in a
naturalistic setting to validate the preliminary find-
ings of this model and generate guidelines based
on real-life data.
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